Hot or Not, Stock Market Edition: 04/29/2025

What’s hot and what’s not in the market so far this week? Let’s take a look: 

• HOT: Both Encompass Health (EHC) and Comfort Systems USA (FIX) enjoy surges following strong earnings
• NOT: Saia (SAIA) falls following earnings; the strange story of Summit Therapeutics (SMMT)

P.S. For more stocks making moves, check out our new Zen Ratings Upgrades & Downgrades screener.

🔥 HOT: Comfort Systems USA (NYSE: FIX) gained 5.6% on Friday after reporting upbeat earnings after the bell on Thursday. The company’s EPS rose 77% year-over-year, and its revenue surpassed analysts’ predictions by $65.18 million. FIX is still down 7.5% YTD but has steadily climbed since its yearly low on April 7th. The company’s financials are incredibly strong, earning it an A rating, and Sentiment and Growth are both solid B’s. While the stock has been more volatile than usual this year, it’s not enough to prevent us from giving FIX a B Zen Rating and a Buy recommendation.

🥶 NOT: Trucking company Saia (NASDAQ: SAIA) lost 30.7% on Friday after its first-quarter earnings fell well short of expectations. The company’s EPS was 32.6% lower than Wall Street predicted, and its revenue fell short of predictions by $25.3 million. SAIA has been beaten down this year and is now down 46.4% YTD. Growth, Momentum, and Sentiment all get D ratings in our internal analysis, ultimately leading to a Zen Rating of D and a Sell recommendation.

🔥 HOT: Shares of Encompass Health (NYSE: EHC) surged to gain 11.8% on Friday after the company beat its earnings projections and issued strong guidance for the remainder of the year. The company’s first-quarter EPS exceeded Wall Street’s expectation by 15.4%, and its revenue came in $25.7 million above the consensus estimate. The company has gained 22.5%, which is no small feat given the state of the market so far in 2025. We give EHC B ratings in Sentiment, Safety, and Financials, and an overall Zen Rating of B.

🥶 NOT: Shares of Summit Therapeutics (NASDAQ: SMMT) cratered for a 36.1% loss on Friday before being halted at 12:35 for a pending news release. The stock was previously riding high from the recent drug trial results for its new cancer treatment, ivonescimab. It is unclear what caused the flash crash as of this writing. Our Zen Rating for SMMT is a C, and the D rating in Safety is what makes recommending SMMT and other, similar biopharmaceutical stocks difficult. SMMT was trading at $35.92 per share before the crash and fell to $23.21 before being halted.

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.